With a progressive strategy that's "building an ecosystem," Biondvax Pharmaceuticals Ltd. offered upbeat preliminary results from the BVX-006 phase II trial gauging the worth of M-001 in the Ness Ziona, Israel-based firm's quest for a universal influenza vaccine, and analyst Ashok Kumar at Aegis Capital Corp. tagged what could be alluring prospects for would-be partners or buyers of the firm.